Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study |
| Type de publication | Journal Article |
| Year of Publication | 2015 |
| Auteurs | Zuily S, de Laat B, Mohamed S, Kelchtermans H, Shums Z, Albesa R, Norman GL, Lamboux-Matthieu C, Rat A-C, Ninet J, Magy-Bertrand N, Pasquali J-L, Lambert M, Lorcerie B, Kaminsky P, Guillemin F, Regnault V, Wahl D, Investigators TACIT |
| Journal | RHEUMATOLOGY |
| Volume | 54 |
| Pagination | 2071-2075 |
| Date Published | NOV |
| Type of Article | Article |
| ISSN | 1462-0324 |
| Mots-clés | anti-phosphatidylserine/prothrombin antibodies, Antiphospholipid syndrome, global APS score, Systemic lupus erythematosus, thrombosis |
| Résumé | {Objective. To investigate the validity of the global APS score (GAPSS) to predict thrombosis in patients with autoimmune diseases. Methods. This prospective cohort study included consecutive patients with aPL or SLE. aPL, aPS-PT and GAPSS were determined. A Cox proportional hazards model assessed the validity of GAPSS and identified other potential independent predictors of thrombosis. Results. One hundred and thirty-seven patients [43.5 (S.D. 15.4) years old; 107 women] were followed up for a mean duration of 43.1 (S.D. 20.7) months. Mean GAPSS was significantly higher in patients who experienced a thrombotic event compared with those without [10.88 (S.D. 5.06) vs 8.15 (S.D. 5.31), respectively |
| DOI | 10.1093/rheumatology/kev238 |